Innovations for Patients
We combine research with market access and patient access
Our Vission: Access to Progress for All
Our Mission: Deploy – Implement – Enforce:
Make Innovation Possible
When research is published new obstacles arise blocking application and availability, like bureaucratic or financial obstacles.
Our focus is on research of rare deseases, highly innovative therapies and access to them long before approval.
Our goal:
The actual use of therapies that are needed. Worldwide. In compliance with obligations.
People in the event of illness shall receive the therapy that corresponds to the current state of medical science and is economically justifiable
Our Way:
Research –> Market Access –> Patient Access
Our Services
Supply
Legally, scientifically and economically oriented improvement of patients’ access to medically necessary services- Rapid access to healthcare innovation
- Development of legally compliant supply solutions for the use of pharmaceuticals (including “expensive products”, orphan drugs, “expensive” drugs)
- Platform for the establishment of legally compliant supply solutions (especially pharmaceuticals, medical devices)
- Organization of Early Access Programs (Compassionate Use, Individual Healing Attempt, Framework for Early Access)
- Information platform for therapies for specific diseases (Phase I, I, III)
- Organizational services
- Acting as an interdisciplinary negotiation team in questions of systemic security of supply in the resolution of conflicts of interest (purchasing – use of technologies)
- Insurance organisation for liability issues (doctors’ liability)
- Organization of legal representation of companies, persons, patients in courts (RA)
- Support
- Legally compliant support for stakeholders within the framework of the evaluation board according to § 62c KAKuG and the hospital laws of the federal states
- Strengthening patients’ access to necessary forms of therapy, including financing solutions
- Supporting stakeholders in establishing legal and supply certainty in all areas of the healthcare system
- Support for legal, scientific, economic evaluation
- Critical assessment of the implementation of Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU in Austria
- Mediator between conflicts of interest between the purchase and sale of medicines and medical devices
- Critical evaluation of HTA assessments or reviews
- Ensuring the use of legally developed products